Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.51 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760088 | 0.98 | CYP1A2 (0.62) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL11093962 | 0.95 | LMNA (0.60) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL13199362 | 0.88 | LMNA (0.63) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL591921 | 0.83 | LMNA (0.51) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL11399957 | 0.81 | SMN1; SMN2 (0.52) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL16574247 | 0.81 | LMNA (0.60) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL3568484 | 0.81 | LMNA (0.52) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL13261412 | 0.81 | TK1 (0.62) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL9803023 | 0.80 | LMNA (0.58) | CYP1A2KMT2ALMNASMN1; SMN2CYP3A4 | |
| SCHEMBL11397970 | 0.80 | SMN1; SMN2 (0.51) | CYP1A2KMT2ACYP2C19CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0062068-B1 | N-PHTHALIDYL-5-FLUOROURACIL DERIVATIVES | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1985-06-12 | — | — | EP | claimed |
| JP-55079377-A | — | — | None | — | — | JP | disclosed |
| JP-55129272-A | — | — | None | — | — | JP | disclosed |
| JP-56016474-A | — | — | None | — | — | JP | disclosed |
| CN-109384730-A | 1- { 3- [p- double-(2- chloroethyl) amido] phenylpropyl alcohol amido } formyl -5-fluor-uracil and preparation and application | 南京友怡医药科技有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-109384776-A | A kind of 5-fluor-uracil derivative and its preparation method and application | 南京友怡医药科技有限公司 | 2019-02-26 | — | — | CN | disclosed |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| EP-0062068-A1 | N-PHTHALIDYL-5-FLUOROURACIL DERIVATIVES | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1982-10-13 | — | — | EP | disclosed |
| JP-S5616474-A | 5-FLUOROURACIL DERIVATIVE | GRELAN PHARMACEUT CO LTD | 1981-02-17 | — | — | JP | disclosed |
| JP-S55129272-A | 5-FLUOROURACIL DERIVATIVE AND ITS PREPARATION | GRELAN PHARMACEUT CO LTD | 1980-10-06 | — | — | JP | disclosed |
| JP-S5579377-A | SYNTHESIS OF 3-ACYL-5-FLUOROURACIL | GRELAN PHARMACEUT CO LTD | 1980-06-14 | — | — | JP | disclosed |
| US-4088646-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | CYP1A2 3244/4885KMT2A 528/4885CYP2C19 4523/4885 |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | RNMT, NUDT1, NTPCR | CYP1A2 3244/4885KMT2A 528/4885CYP2C19 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.